Prudential Financial’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-59,040
| Closed | -$894K | – | 2745 |
|
|
2022
Q3 | $894K | Buy |
+59,040
| New | +$686K | ﹤0.01% | 1816 |
|
|
2022
Q2 | – | Sell |
-39,350
| Closed | -$358K | – | 2789 |
|
|
2022
Q1 | $358K | Buy |
+39,350
| New | +$303K | ﹤0.01% | 2330 |
|
|
2019
Q4 | – | Sell |
-282,000
| Closed | -$5.73M | – | 2497 |
|
|
2019
Q3 | $5.73M | Buy |
282,000
+100,989
| +56% | +$2.31M | 0.01% | 1053 |
|
|
2019
Q2 | $5.35M | Buy |
181,011
+80,140
| +79% | +$3.09M | 0.01% | 1116 |
|
|
2019
Q1 | $4.79M | Sell |
100,871
-57,090
| -36% | -$2.51M | 0.01% | 1153 |
|
|
2018
Q4 | $5.61M | Buy |
157,961
+45,860
| +41% | +$2.15M | 0.01% | 1052 |
|
|
2018
Q3 | $6.9M | Buy |
112,101
+64,360
| +135% | +$4.14M | 0.01% | 1051 |
|
|
2018
Q2 | $3.23M | Sell |
47,741
-10,169
| -18% | -$569K | ﹤0.01% | 1418 |
|
|
2018
Q1 | $3.14M | Buy |
57,910
+4,890
| +9% | +$273K | ﹤0.01% | 1367 |
|
|
2017
Q4 | $3.28M | Sell |
53,020
-3,500
| -6% | -$212K | ﹤0.01% | 1338 |
|
|
2017
Q3 | $2.75M | Sell |
56,520
-26,070
| -32% | -$1.42M | ﹤0.01% | 1419 |
|
|
2017
Q2 | $4.34M | Buy |
82,590
+19,060
| +30% | +$887K | 0.01% | 1202 |
|
|
2017
Q1 | $2.88M | Buy |
+63,530
| New | +$2.83M | ﹤0.01% | 1383 |
|
Prudential Financial's AERI Position: Q4 2022 in Review
Prudential Financial sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 59,040 shares — an estimated $894K sold.
Prudential Financial first reported a position in AERI in Q1 2017 and held it in 13 quarters. The position peaked at $6.9M in Q3 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Prudential Financial reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Prudential Financial sold 59,040 Aerie Pharmaceuticals shares in Q4 2022, an estimated $894K.
- Prudential Financial first reported a position in Aerie Pharmaceuticals in Q1 2017 and held it in 13 quarters.
- Prudential Financial's Aerie Pharmaceuticals position peaked at $6.9M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Prudential Financial's 13F filing for Q4 2022, filed 14 Feb 2023.